These agreements have an initial term to 2011 and effectively extend and strengthen existing distribution arrangements, giving Abbott and PSS exclusive marketing rights to the Afinion system in the US.
Ian Gilham, CEO of Axis-Shield, said: “These agreements reflect the commitment of Abbott and PSS to Afinion and its proven superiority for measuring HbA1c at the point of care. We look forward to increasing sales of our flagship Afinion system in the important US market.”